Educational material about research-use reagents; not instructions for human use.

A search for Mounjaro or munjaro usually means the prescription brand name, not INN tirzepatide on an RUO vial. Below: what Mounjaro and tirzepatide are, how the dual GIP/GLP-1 axis differs from GLP-1-only agonists, where the pharmacy brand ends and the research sample begins, and how to verify a LOT via COA.

What Mounjaro is and what tirzepatide is

Mounjaro and Zepbound are trademarks for finished injectable drug products from Eli Lilly. The active ingredient in both is tirzepatide (INN), a synthetic dual incretin agonist peptide.

The brand vs molecule split is the same as Ozempic ↔ semaglutide or Saxenda ↔ liraglutide: the trademark binds a specific dosage form, indication set, and regulatory status; the INN names the chemical entity regardless of packaging.

The Longeva hub does not sell Mounjaro, Zepbound, or other pharmacy brands. We publish trademark editorials on the apex; the commercial GLP-1/GIP RUO sample lives under Incretin: tirzepatide card.

Dual GIP/GLP-1: how tirzepatide differs from GLP-1-only

Semaglutide and liraglutide act mainly on the GLP-1 receptor. Tirzepatide adds a second axis, GIP (glucose-dependent insulinotropic polypeptide), hence dual incretin agonist: one molecule, two incretin receptor targets.

  • GLP-1 axis. Satiety, gastric emptying, glucose-dependent insulin (shared logic with other GLP-1 agonists).
  • GIP axis. An additional incretin pathway not activated the same way by mono-GLP-1 drugs.
  • Third axis (glucagon). Not present in tirzepatide; triple agonism with glucagon is retatrutide on Tripept. Map of all three axes: GLP-1, GIP and glucagon.

Clinical programs SURPASS (type 2 diabetes) and SURMOUNT (body weight) studied branded tirzepatide in prescription forms. That is class context, not an RUO protocol. Deeper RUO framing on Incretin: SURPASS/SURMOUNT and the research sample.

Mounjaro, Zepbound, Ozempic: how they differ

BrandINNReceptor profileTypical search intent
MounjarotirzepatideGLP-1 + GIPtype 2 diabetes
ZepboundtirzepatideGLP-1 + GIPbody weight (US)
Ozempic / WegovysemaglutideGLP-1 monodiabetes / weight
RUO tirzepatidetirzepatidesame moleculelab sample, not a drug product

Mounjaro and Zepbound share the same molecule (tirzepatide) under different brand lines and registered indications. Ozempic is a different molecule (semaglutide). Brand comparison: Mounjaro vs Ozempic; RUO sample choice: tirzepatide vs semaglutide.

Mounjaro analogues: pharmacy brand vs research-use tirzepatide

When people search for Mounjaro analogues they usually mean one of two things:

  1. Other prescription incretin drugs, Ozempic/Wegovy (semaglutide), Saxenda (liraglutide). Pharmacy path: prescription, price, shortages.
  2. Research-use tirzepatide, the same INN as lyophilized research material without brand markup, and without pharmacy quality guarantees. Label status: Research Use Only (RUO), not for human use.

Longeva covers the second layer, the laboratory context. Incretin runs the commercial GLP-1 and GIP catalogue, while this side navigates trademarks, monographs, and sample cards. A fuller look at the class: GLP-1 guide on Incretin. Weight-loss selection: peptides for weight loss.

How to tell real tirzepatide from a fake: COA and LOT verification

  • COA (Certificate of Analysis) per batch (LOT): identity and purity from a third-party lab. A listing title saying Mounjaro without COA does not prove tirzepatide inside the vial.
  • LOT match. Vial batch number must match the PDF in the COA archive; verify at /verify/{lot}.
  • Red flags: no COA; one certificate for all batches; messenger-only seller; price far below market for the claimed purity; relabeled vials with a brand name and no lab document.

Same rule as semaglutide and liraglutide: verifiable purity beats price.

Price and availability in Ukraine

Branded Mounjaro at a pharmacy requires a prescription, carries a high price, and is often in short supply. Research-use tirzepatide is cheaper in the research segment but shifts all quality responsibility to the buyer: COA and LOT checks are mandatory, not optional.

Trademarks. Mounjaro® and Zepbound® are Eli Lilly; Ozempic®, Wegovy®, and Rybelsus® are Novo Nordisk; Saxenda® and Victoza® are Novo Nordisk. Longeva is not affiliated with these manufacturers and does not sell their drug products.